Key Takeaways: L’Oréal’s pivot toward luxury, fragrance, and medical dermatology has fundamentally reshaped its growth and earnings profile.Targeted M&A has transformed L’Oréal’s revenue mix in recent years, narrowing the gap between consumer, luxury, and clinical divisions while accelerating growth in haircare.Medical aesthetics is going mainstream, pulling beauty closer to healthcare and redefining how consumers approach skincare.L’Oréal’s bet that premiumizing its portfolio could sustain its competitive edge is paying off.The French beauty group is in its strongest position to date, helped by a decade-long strategic pivot toward luxury and dermatological beauty, mainly driven by targeted acquisitions under Chief Executive Nicolas Hieronimus. After taking the helm in May 2021 following a decades-long career at the company, his mergers and acquisitions strategy has nearly doubled sales in recent years, cementing L’Oréal’s position as the largest beauty player in the US, with a market share of roughly 13%, as well as making it the luxury beauty leader in North Asia.“2025 was a defining year for L’Oréal: we delivered strong results regardless of the context, while profoundly transforming the group,” Hieronimus said after reporting the company’s annual earnings. “It’s been a record year in terms of acquisitions,” he added at the Consumer Analyst Group of New York (CAGNY) conference in Orlando last month, underscoring the scale of the group’s strategic transformation.